Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice

Arthritis and Rheumatism

Volumn 63, Issue 7, 2011, Pages 2038-2048

  Hsu, Hui Chen ^a   Yang, Pingar ^a   Wu, Qi ^a   Wang, John H ^a   Job, Godwin ^a   Guentert, Tanja ^a   Li, Jun ^a   Stockard, Cecil R ^a   Le, Thuc Vy L ^b   Chaplin, David D ^a   Grizzle, William E ^a   Mountz, John D ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EMORY UNIVERSITY   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; AUTOANTIBODY; CASPASE 9; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GERMINAL CENTER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SOMATIC HYPERMUTATION;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; B-LYMPHOCYTES; CATALYTIC DOMAIN; CYTIDINE DEAMINASE; DNA DAMAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GERMINAL CENTER; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79955571648     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30257     Document Type: Article

References (50)

1. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33. (Pubitemid 37255038)
2. Rantapaa-Dahlqvist S, De Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9. (Pubitemid 37280601)
3. Li QZ, Xie C, Wu T, Mackay M, Aranow C, Putterman C, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005; 115: 3428-39. (Pubitemid 43121831)
4. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52: 239-46. (Pubitemid 40129253)
5. Longerich S, Basu U, Alt F, Storb U,. AID in somatic hypermutation and class switch recombination. Curr Opin Immunol 2006; 18: 164-74. (Pubitemid 43327298)
6. Honjo T, Muramatsu M, Fagarasan S,. AID: how does it aid antibody diversity? Immunity 2004; 20: 659-68. (Pubitemid 38757437)
7. Xu X, Hsu HC, Chen J, Grizzle WE, Chatham WW, Stockard CR, et al. Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis. Scand J Immunol 2009; 70: 309-16.
8. Keystone E,. B cell targeted therapies. Arthritis Res Ther 2005; 7 Suppl 3: S13-8. (Pubitemid 40936612)
9. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81. (Pubitemid 38758544)
10. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806. (Pubitemid 44497758)
11. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al, for the Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab Registry. Arthritis Rheum 2010; 62: 2458-66.
12. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab trial. Arthritis Rheum 2010; 62: 222-33.
13. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-54. (Pubitemid 36959194)
14. Rouziere AS, Kneitz C, Palanichamy A, Dorner T, Tony HP,. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 2005; 7: R714-24.
15. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20. (Pubitemid 43228639)
16. Looney RJ, Anolik J, Sanz I,. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 180-5. (Pubitemid 38530483)
17. Daridon C, Burmester GR, Dorner T,. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr Opin Rheumatol 2009; 21: 205-10.
18. Han S, Zhang X, Marinova E, Ozen Z, Bheekha-Escura R, Guo L, et al. Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response. Arthritis Rheum 2005; 52: 3202-9. (Pubitemid 41447103)
19. Hsu HC, Wu Y, Yang P, Wu Q, Job G, Chen J, et al. Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. J Immunol 2007; 178: 5357-65. (Pubitemid 46595322)
20. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9: 166-75.
21. Fagarasan S, Muramatsu M, Suzuki K, Nagaoka H, Hiai H, Honjo T,. Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 2002; 298: 1424-7. (Pubitemid 35346143)
22. Hase K, Takahashi D, Ebisawa M, Kawano S, Itoh K, Ohno H,. Activation-induced cytidine deaminase deficiency causes organ-specific autoimmune disease. PLoS One 2008; 3: e3033.
23. Zaheen A, Boulianne B, Parsa JY, Ramachandran S, Gommerman JL, Martin A,. AID constrains germinal center size by rendering B cells susceptible to apoptosis. Blood 2009; 114: 547-54.
24. Papavasiliou FN, Schatz DG,. The activation-induced deaminase functions in a postcleavage step of the somatic hypermutation process. J Exp Med 2002; 195: 1193-8. (Pubitemid 34517145)
25. Basu U, Chaudhuri J, Alpert C, Dutt S, Ranganath S, Li G, et al. The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature 2005; 438: 508-11. (Pubitemid 41742023)
26. Wang JH, Li J, Wu Q, Yang P, Pawar RD, Xie S, et al. Marginal zone precursor B cells as cellular agents for type I IFN-promoted antigen transport in autoimmunity. J Immunol 2010; 184: 442-51.
27. Kelsoe G, Reth M, Rajewsky K,. Control of idiotope expression by monoclonal anti-idiotope and idiotope-bearing antibody. Eur J Immunol 1981; 11: 418-23. (Pubitemid 11072565)
28. Hsu HC, Zhou T, Kim H, Barnes S, Yang P, Wu Q, et al. Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritis. Arthritis Rheum 2006; 54: 343-55. (Pubitemid 43122218)
29. Hsu HC, Zhang HG, Song GG, Xie J, Liu D, Yang P, et al. Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection. Arthritis Rheum 2001; 44: 2146-59. (Pubitemid 33644060)
30. Xie S, Li J, Wang JH, Wu Q, Yang P, Hsu HC, et al. IL-17 activates the canonical NF-ÎB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of G-protein signaling 16. J Immunol 2010; 184: 2289-96.
31. Allman D, Pillai S,. Peripheral B cell subsets. Curr Opin Immunol 2008; 20: 149-57.
32. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999; 274: 18470-6.
33. Tran TH, Nakata M, Suzuki K, Begum NA, Shinkura R, Fagarasan S, et al. B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat Immunol 2010; 11: 148-54.
34. Takahashi Y, Dutta PR, Cerasoli DM, Kelsoe G,. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J Exp Med 1998; 187: 885-95. (Pubitemid 28141662)
35. Mountz JD, Yang P, Wu Q, Zhou J, Tousson A, Fitzgerald A, et al. Genetic segregation of spontaneous erosive arthritis and generalized autoimmune disease in the BXD2 recombinant inbred strain of mice. Scand J Immunol 2005; 61: 128-38. (Pubitemid 40255356)
36. Van der Voort R, Taher TE, Keehnen RM, Smit L, Groenink M, Pals ST,. Paracrine regulation of germinal center B cell adhesion through the c-Met-hepatocyte growth factor/scatter factor pathway. J Exp Med 1997; 185: 2121-31. (Pubitemid 27265996)
37. Choi Y,. Differentiation and apoptosis of human germinal center B-lymphocytes. Immunol Res 1997; 16: 161-74. (Pubitemid 27294587)
38. Bouchon A, Krammer PH, Walczak H,. Critical role for mitochondria in B cell receptor-mediated apoptosis. Eur J Immunol 2000; 30: 69-77. (Pubitemid 30011767)
39. Herold MJ, Kuss AW, Kraus C, Berberich I,. Mitochondria-dependent caspase-9 activation is necessary for antigen receptor-mediated effector caspase activation and apoptosis in WEHI 231 lymphoma cells. J Immunol 2002; 168: 3902-9. (Pubitemid 34298393)
40. Lee-Theilen M, Chaudhuri J,. Walking the AID tightrope. Nat Immunol 2010; 11: 107-9.
41. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009; 6: e1.
42. Jiang C, Foley J, Clayton N, Kissling G, Jokinen M, Herbert R, et al. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J Immunol 2007; 178: 7422-31. (Pubitemid 46847470)
43. Jiang C, Zhao ML, Diaz M,. Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis. Immunology 2009; 126: 102-13.
44. Kasahara Y, Kaneko H, Fukao T, Terada T, Asano T, Kasahara K, et al. Hyper-IgM syndrome with putative dominant negative mutation in activation-induced cytidine deaminase. J Allergy Clin Immunol 2003; 112: 755-60. (Pubitemid 37260393)
45. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T,. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 553-63.
46. Bergthorsdottir S, Gallagher A, Jainandunsing S, Cockayne D, Sutton J, Leanderson T, et al. Signals that initiate somatic hypermutation of B cells in vitro. J Immunol 2001; 166: 2228-34. (Pubitemid 32173452)
47. Kallberg E, Jainandunsing S, Gray D, Leanderson T,. Somatic mutation of immunoglobulin V genes in vitro. Science 1996; 271: 1285-9. (Pubitemid 26082650)
48. Anderson SM, Khalil A, Uduman M, Hershberg U, Louzoun Y, Haberman AM, et al. Taking advantage: high-affinity B cells in the germinal center have lower death rates, but similar rates of division, compared to low-affinity cells. J Immunol 2009; 183: 7314-25.
49. Isenberg DA,. B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 2006; 77: 24-8.
50. Silverman GJ,. Targeting of B cells in SLE: rationale and therapeutic opportunities. Bull NYU Hosp Jt Dis 2006; 64: 51-6. (Pubitemid 44625533)